Price (delayed)
$0.6983
Market cap
$31.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.63
Enterprise value
-$42.61M
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its ...
Highlights
Werewolf Therapeutics's debt has decreased by 29% YoY
The quick ratio has declined by 26% since the previous quarter but it has increased by 4.4% year-on-year
The gross profit has plunged by 91% YoY and by 44% from the previous quarter
Werewolf Therapeutics's revenue has plunged by 91% YoY and by 44% from the previous quarter
Key stats
What are the main financial stats of HOWL
MarketValuationsEarnings
Shares outstanding
44.83M
Market cap
$31.3M
Enterprise value
-$42.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.42
Price to sales (P/S)
16.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-22.6
Revenue
$1.89M
Gross profit
$1.89M
Operating income
-$73.59M
Net income
-$70.52M
EBIT
-$65.86M
EBITDA
-$63.16M
Free cash flow
-$56.44M
Per shareBalance sheetLiquidity
EPS
-$1.63
EPS diluted
-$1.63
Free cash flow per share
-$1.3
Book value per share
$1.65
Revenue per share
$0.04
TBVPS
$2.93
Total assets
$126.93M
Total liabilities
$53.54M
Debt
$37.09M
Equity
$73.39M
Working capital
$97.89M
Debt to equity
0.51
Current ratio
7.45
Quick ratio
7.31
Net debt/EBITDA
1.17
MarginsEfficiencyDividend
EBITDA margin
-3,350.6%
Gross margin
100%
Net margin
-3,740.8%
Operating margin
-3,904.2%
Return on assets
-47.1%
Return on equity
-73.4%
Return on invested capital
-137.6%
Return on capital employed
-58.9%
Return on sales
-3,493.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HOWL stock price
How has the Werewolf Therapeutics stock price performed over time
Intraday
-11.9%
1 week
-32.2%
1 month
-40.32%
1 year
-88.36%
YTD
-52.82%
QTD
-28.17%
Financial performance
How have Werewolf Therapeutics's revenue and profit performed over time
Revenue
$1.89M
Gross profit
$1.89M
Operating income
-$73.59M
Net income
-$70.52M
Gross margin
100%
Net margin
-3,740.8%
HOWL financials
Werewolf Therapeutics's net margin has shrunk by 104% QoQ
The company's operating margin has shrunk by 100% QoQ
The gross profit has plunged by 91% YoY and by 44% from the previous quarter
Werewolf Therapeutics's revenue has plunged by 91% YoY and by 44% from the previous quarter
Growth
What is Werewolf Therapeutics's growth rate over time
HOWL growth chart
Valuation
What is Werewolf Therapeutics stock price valuation
P/E
N/A
P/B
0.42
P/S
16.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-22.6
Price to earnings (P/E)
HOWL's EPS has plunged by 55% YoY and by 9% from the previous quarter
Price to book (P/B)
HOWL's price to book (P/B) is 68% lower than its last 4 quarters average of 1.3
The equity has contracted by 34% YoY and by 18% from the previous quarter
Price to sales (P/S)
Werewolf Therapeutics's revenue has plunged by 91% YoY and by 44% from the previous quarter
HOWL's price to sales (P/S) is 28% lower than its last 4 quarters average of 22.4
Efficiency
How efficient is Werewolf Therapeutics business performance
HOWL's ROIC has shrunk by 181% YoY and by 35% QoQ
Werewolf Therapeutics's return on assets has shrunk by 131% YoY and by 22% QoQ
Werewolf Therapeutics's return on equity has shrunk by 128% YoY and by 25% QoQ
HOWL's ROS has plunged by 105% from the previous quarter
Dividends
What is HOWL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HOWL.
Financial health
How did Werewolf Therapeutics financials performed over time
Assets vs liabilities
The total assets is 137% higher than the total liabilities
The total assets is down by 27% YoY and by 9% QoQ
The quick ratio has declined by 26% since the previous quarter but it has increased by 4.4% year-on-year
Debt vs equity
Werewolf Therapeutics's debt is 49% lower than its equity
The equity has contracted by 34% YoY and by 18% from the previous quarter
Werewolf Therapeutics's debt has decreased by 29% YoY
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.